Literature DB >> 25348781

A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.

Stephanie Downs-Canner1, Ying Ding, Deepa R Magge, Heather Jones, Lekshmi Ramalingam, Amer Zureikat, Matthew Holtzman, Steven Ahrendt, James Pingpank, Herbert J Zeh, David L Bartlett, Haroon A Choudry.   

Abstract

BACKGROUND: Postoperative pancreatic fistulas (POPFs) are potentially morbid complications that often require therapeutic interventions. Distal pancreatectomy performed during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) puts patients at risk for POPF. The authors hypothesized that POPFs are more severe after CRS/HIPEC than after pancreatectomy alone.
METHODS: Clinicopathologic and perioperative details, including POPF by International Study Group of Pancreatic Fistula criteria (ISGPF), and oncologic outcomes for patients undergoing distal pancreatectomy during CRS/HIPEC for peritoneal carcinomatosis of appendiceal (n = 31) or colorectal (n = 23) origin (HIPEC group) were compared with those for patients undergoing minimally invasive or open distal pancreatectomy without HIPEC (n = 66) for locally resectable pancreatic adenocarcinoma (non-HIPEC group).
RESULTS: The incidence of POPF was similar between the HIPEC and non-HIPEC groups (26 %). The severity of POPF according to the ISGPF criteria was significantly worse in the HIPEC group. The HIPEC patients had 13 grade B fistulas and 1 grade C fistula compared with 12 grade A fistulas and 4 grade B fistulas in the non-HIPEC group. The HIPEC patients with POPF did not differ in the extent of their CRS, peritoneal cancer index, length of hospital stay, or other postoperative complications from the the HIPEC patients without POPF. The HIPEC patients with colorectal carcinomatosis who experienced POPF had higher disease recurrence in the first year after CRS/HIPEC than those without POPF.
CONCLUSION: The findings showed that POPFs are more severe when distal pancreatectomy is combined with CRS/HIPEC. Moreover, selective use of distal pancreatectomy is important during CRS/HIPEC because POPFs may increase early disease recurrence for patients with colorectal carcinomatosis.

Entities:  

Mesh:

Year:  2014        PMID: 25348781      PMCID: PMC4537169          DOI: 10.1245/s10434-014-4186-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  32 in total

1.  Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.

Authors:  O Glehen; D Osinsky; E Cotte; F Kwiatkowski; G Freyer; S Isaac; V Trillet-Lenoir; A C Sayag-Beaujard; Y François; J Vignal; F N Gilly
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

Review 2.  Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results.

Authors:  Terence C Chua; Greg Robertson; Winston Liauw; Rhonda Farrell; Tristan D Yan; David L Morris
Journal:  J Cancer Res Clin Oncol       Date:  2009-08-23       Impact factor: 4.553

3.  Volume therapy and cardiocircular function during hyperthermic intraperitoneal chemotherapy.

Authors:  W Raue; N Tsilimparis; A Bloch; C Menenakos; J Hartmann
Journal:  Eur Surg Res       Date:  2009-10-17       Impact factor: 1.745

Review 4.  Prevention and treatment of complications in pancreatic cancer surgery.

Authors:  P O Berberat; H Friess; J Kleeff; W Uhl; M W Büchler
Journal:  Dig Surg       Date:  1999       Impact factor: 2.588

5.  Management of pancreatic fistulas after a splenectomy as part of cytoreductive surgery for ovarian cancer.

Authors:  Kazuyoshi Kato; Shinichi Tate; Kyoko Nishikimi; Makio Shozu
Journal:  Int J Gynecol Cancer       Date:  2013-10       Impact factor: 3.437

6.  Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status.

Authors:  Chukwuemeka U Ihemelandu; Richard McQuellon; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2013-06-08       Impact factor: 5.344

7.  Factors influencing early postoperative recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  E Arakelian; L Gunningberg; J Larsson; K Norlén; H Mahteme
Journal:  Eur J Surg Oncol       Date:  2011-07-23       Impact factor: 4.424

8.  Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced ovarian, peritoneal and fallopian tube cancer.

Authors:  Siobhan M Kehoe; Eric L Eisenhauer; Nadeem R Abu-Rustum; Yukio Sonoda; Michael D'Angelica; William R Jarnagin; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2008-12-17       Impact factor: 5.482

9.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

Review 10.  Surgical techniques in visceral resection and peritonectomy procedures.

Authors:  Philip Bao; David Bartlett
Journal:  Cancer J       Date:  2009 May-Jun       Impact factor: 3.360

View more
  6 in total

1.  The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.

Authors:  Alexandre Brind'Amour; Mitchell Webb; Marina Parapini; Lucas Sidéris; Maja Segedi; Stephen W Chung; Stéphanie Chartier-Plante; Pierre Dubé; Charles H Scudamore; Peter T W Kim
Journal:  Clin Exp Metastasis       Date:  2021-01-24       Impact factor: 5.150

Review 2.  Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases.

Authors:  Sanket S Mehta; Maxilliano Gelli; Deepesh Agarwal; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-10

3.  Re-operations for early postoperative complications after CRS and HIPEC: indication, timing, procedure, and outcome.

Authors:  Sebastian Blaj; Sebastian Nedelcut; Max Mayr; Hubert Leebmann; Daniel Leucuta; Gabriel Glockzin; Pompiliu Piso
Journal:  Langenbecks Arch Surg       Date:  2019-07-27       Impact factor: 3.445

Review 4.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

5.  Combined modality therapy including cytoreductive surgery and heated intraperitoneal chemotherapy for synchronous low volume peritoneal carcinomatosis from adenocarcinoma of the tail of pancreas in a BRCA-2 carrier resulting in long-term disease-free survival: A case report.

Authors:  Richard A Hoefer; Chukwuemeka Obiora; Basem Azab; Elizabeth A Harden; John F Kessler
Journal:  Int J Surg Case Rep       Date:  2021-05-29

6.  A Prospective, Phase I/II, Open-Label Pilot Trial to Assess the Safety of Hyperthermic Intraperitoneal Chemotherapy After Oncological Resection of Pancreatic Adenocarcinoma.

Authors:  Can Yurttas; Philipp Horvath; Imma Fischer; Christoph Meisner; Silvio Nadalin; Ingmar Königsrainer; Alfred Königsrainer; Stefan Beckert; Markus W Löffler
Journal:  Ann Surg Oncol       Date:  2021-06-15       Impact factor: 5.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.